{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:40Z","timestamp":1793041960338,"version":"4.5.0"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["72115"],"award-info":[{"award-number":["72115"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.exphem.2026.105444","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:05:25Z","timestamp":1778817925000},"page":"105444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["CD20-targeted immunotherapies in B-cell malignancies: mechanistic and clinical advances"],"prefix":"10.1016","volume":"160","author":[{"given":"Reza","family":"Hasani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mostafa","family":"Pourseif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7481-0896","authenticated-orcid":false,"given":"Effat","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2949-7482","authenticated-orcid":false,"given":"Mohammad Reza","family":"Tohidkia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Rahmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2026.105444_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.exphem.2026.105444_bib0002","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.blre.2018.07.003","article-title":"Evolution of survivorship in lymphoma, myeloma and leukemia: metamorphosis of the field into long term follow-up care","volume":"33","author":"Damlaj","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.exphem.2026.105444_bib0003","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to watch in 2023","volume":"15","author":"Kaplon","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.exphem.2026.105444_bib0004","doi-asserted-by":"crossref","first-page":"601","DOI":"10.21147\/j.issn.1000-9604.2022.06.08","article-title":"A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera(\u00ae) in patients with CD20-positive B-cell non-Hodgkin lymphoma","volume":"34","author":"Han","year":"2022","journal-title":"Chin J Cancer Res."},{"key":"10.1016\/j.exphem.2026.105444_bib0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nri1838","article-title":"B-cell targeting in rheumatoid arthritis and other autoimmune diseases","volume":"6","author":"Edwards","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.exphem.2026.105444_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389201003379059","article-title":"Rituximab: the first monoclonal antibody approved for the treatment of lymphoma","volume":"1","author":"Grillo-L\u00f3pez","year":"2000","journal-title":"Curr Pharm Biotechnol."},{"key":"10.1016\/j.exphem.2026.105444_bib0007","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hon.3054","article-title":"Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera(\u00ae) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: a randomized, single-blind, phase III clinical trial","volume":"40","author":"Shi","year":"2022","journal-title":"Hematol Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0008","article-title":"Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-na\u00efve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial","volume":"12","author":"Li","year":"2024","journal-title":"Immunother Cancer."},{"key":"10.1016\/j.exphem.2026.105444_bib0009","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.2015.61.3968","article-title":"Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35\/03","volume":"34","author":"Taverna","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0010","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0011","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bjh.16264","article-title":"First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4","volume":"188","author":"Walewski","year":"2020","journal-title":"Br J Haematol."},{"key":"10.1016\/j.exphem.2026.105444_bib0012","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0013","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3324\/haematol.2020.274803","article-title":"Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study","volume":"107","author":"Rule","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2026.105444_bib0014","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0015","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1\u20132 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0016","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3109\/10428194.2015.1122783","article-title":"Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia","volume":"57","author":"\u00d6sterborg","year":"2016","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.exphem.2026.105444_bib0017","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1182\/blood-2010-12-323980","article-title":"Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia","volume":"117","author":"Wierda","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0018","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/10428194.2020.1842400","article-title":"Phase I\/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma","volume":"62","author":"Pan","year":"2021","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.exphem.2026.105444_bib0019","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/10428194.2016.1233536","article-title":"Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial","volume":"58","author":"Robak","year":"2017","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.exphem.2026.105444_bib0020","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1002\/cncr.32289","article-title":"Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance)","volume":"125","author":"Blum","year":"2019","journal-title":"Cancer."},{"key":"10.1016\/j.exphem.2026.105444_bib0021","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/annonc\/mdq027","article-title":"Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma","volume":"21","author":"Morschhauser","year":"2010","journal-title":"Ann Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0022","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.14534","article-title":"A phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br J Haematol."},{"key":"10.1016\/j.exphem.2026.105444_bib0023","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood.V124.21.4679.4679","article-title":"Ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib is highly active in patients with relapsed and\/or refractory CLL and MCL; results of a phase II trial","volume":"124","author":"Sharman","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105444_bib0024","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(18)30216-3","article-title":"Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial","volume":"6","author":"Nastoupil","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.exphem.2026.105444_bib0025","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(20)30433-6","article-title":"Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial","volume":"8","author":"Sharman","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.exphem.2026.105444_bib0026","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0027","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/10428194.2024.2310144","article-title":"Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"65","author":"Lei","year":"2024","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.exphem.2026.105444_bib0028","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.exphem.2026.105444_bib0029","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0030","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.exphem.2026.105444_bib0031","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","article-title":"Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000)","volume":"122","author":"Radford","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0032","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.exphem.2026.105444_bib0033","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0034","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","article-title":"A randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final analysis of GOYA","volume":"13","author":"Sehn","year":"2020","journal-title":"J Hematol Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.exphem.2026.105444_bib0036","article-title":"A novel anti-CD20 monoclonal antibody for treating relapsed immune thrombocytopenia","volume":"144","author":"Liu","year":"2024","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102702","article-title":"Efficacy and safety of MIL62, a novel glycoengineered type \u2161 anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed\/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b\/2 trial","volume":"73","author":"Shi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.exphem.2026.105444_bib0038","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s12325-020-01603-8","article-title":"Efficacy and safety of the biosimilar IBI301 plus standard CHOP (I-CHOP) in comparison with rituximab plus CHOP (R-CHOP) in patients with previously untreated Diffuse large B-cell lymphoma (DLBCL): a randomized, double-blind, parallel-group, phase 3 trial","volume":"38","author":"Song","year":"2021","journal-title":"Adv Ther."},{"key":"10.1016\/j.exphem.2026.105444_bib0039","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0040","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0041","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol."},{"key":"10.1016\/j.exphem.2026.105444_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115347","article-title":"Characterization and exploration of an artifact in the reducing capillary electrophoresis-sodium dodecyl sulfate analysis of the \u2018me-too\u2019 drug zuberitamab related to rituximab","volume":"228","author":"Gao","year":"2023","journal-title":"J Pharm Biomed Anal."},{"key":"10.1016\/j.exphem.2026.105444_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115347","article-title":"Characterization and exploration of an artifact in the reducing capillary electrophoresis-sodium dodecyl sulfate analysis of the 'me-too' drug zuberitamab related to rituximab","volume":"228","author":"Gao","year":"2023","journal-title":"J Pharm Biomed Anal."},{"key":"10.1016\/j.exphem.2026.105444_bib0044","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.exphem.2026.105444_bib0045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody\u2013drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0046","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-021-01097-z","article-title":"Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress","volume":"14","author":"Chu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2026.105444_bib0047","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.5112.5112","article-title":"Phase I\/Ib study of the novel immunotoxin MT-3724 relapsed\/refractory non-Hodgkin's B-cell lymphoma (NHL)","volume":"126","author":"Hamlin","year":"2015","journal-title":"blood"},{"issue":"Supplement 1","key":"10.1016\/j.exphem.2026.105444_bib0048","article-title":"Monotherapy activity with the first CD20-targeted immunotoxin, MT-3724 subjects with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"134","author":"Hamlin","year":"2019","journal-title":"blood"},{"key":"10.1016\/j.exphem.2026.105444_bib0049","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene."},{"key":"10.1016\/j.exphem.2026.105444_bib0050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1158\/2767-9764.CRC-22-0056","article-title":"Safety and efficacy of engineered toxin body MT-3724 relapsed or refractory B-cell non-Hodgkin's lymphomas and diffuse large B-cell lymphoma","volume":"2","author":"Hamlin","year":"2022","journal-title":"Cancer Res Commun."},{"issue":"Supplement 1","key":"10.1016\/j.exphem.2026.105444_bib0051","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1182\/blood-2021-144829","article-title":"A dose escalation phase Ia study of anti-CD20 antibody drug conjugate, MRG001 relapsed\/refractory advanced non-Hodgkin lymphoma","volume":"138","author":"Song","year":"2021","journal-title":"bBloodlood"},{"key":"10.1016\/j.exphem.2026.105444_bib0052","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/ijc.30569","article-title":"Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix","volume":"140","author":"G\u00e9bleux","year":"2017","journal-title":"Int J Cancer."},{"issue":"Supplement 1","key":"10.1016\/j.exphem.2026.105444_bib0053","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-189675","article-title":"A phase Ib open-label study of MRG001 patients with relapsed or refractory diffuse large B-cell lymphoma (R\/R DLBCL)","volume":"142","author":"Zhu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105444_bib0054","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific antibody based therapeutics: strengths and challenges","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.exphem.2026.105444_bib0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med."},{"key":"10.1016\/j.exphem.2026.105444_bib0056","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cts.12459","article-title":"Clinical pharmacology and translational aspects of bispecific antibodies","volume":"10","author":"Trivedi","year":"2017","journal-title":"Clin Transl Sci."},{"key":"10.1016\/j.exphem.2026.105444_bib0057","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","article-title":"Bispecific, T-cell-recruiting antibodies in B-cell malignancies","volume":"11","author":"Lejeune","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.exphem.2026.105444_bib0058","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1182\/blood-2023-187614","article-title":"A CD19\/CD20-directed bispecific CAR-T cell therapy in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL)","volume":"142","author":"Larson","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0059","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1182\/blood-2021-146638","article-title":"Phase 1\/2 trial of IL7\/IL15-expanded bispecific LV20.19 CAR T-cells for relapsed, refractory B-cell non-Hodgkin lymphoma","volume":"138","author":"Shah","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0060","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.exphem.2026.105444_bib0061","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0062","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med."},{"key":"10.1016\/j.exphem.2026.105444_bib0063","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1182\/bloodadvances.2023010840","article-title":"Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study","volume":"7","author":"Olszewski","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.exphem.2026.105444_bib0064","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular lymphoma: initial results from a phase Ib study","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0065","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.7020","article-title":"Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R\/R) non-Hodgkin lymphoma (NHL): results from a phase I\/II study","volume":"42","author":"Bartlett","year":"2024","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0066","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s43018-025-00941-2","article-title":"Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study","volume":"6","author":"Cartron","year":"2025","journal-title":"Nat Cancer."},{"key":"10.1016\/j.exphem.2026.105444_bib0067","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood-2021-148359","article-title":"Glofitamab (Glofit) in combination with polatuzumab vedotin (Pola): phase Ib\/II preliminary data support manageable safety and encouraging effficacy in relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"138","author":"Hutchings","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105444_bib0068","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/blood-2021-147780","volume":"138","author":"Ghosh","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0069","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.7037","article-title":"Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: updated results from EPCORE NHL-2","volume":"42","author":"Brody","year":"2024","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0071","doi-asserted-by":"crossref","unstructured":"Sehn LH, Chamuleau M, Lenz G, et al. Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (PTS) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2. Hematol Oncol. 2023;41:849\u2013850. doi: 10.1002\/hon.3166_OT28","DOI":"10.1002\/hon.3166_OT28"},{"key":"10.1016\/j.exphem.2026.105444_bib0072","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-179887","article-title":"Epcoritamab SC monotherapy leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: first data disclosure from the Epcore NHL-1 follicular lymphoma dose-expansion cohort","volume":"142","author":"Linton","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0073","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2022-158298","article-title":"Subcutaneous epcoritamab in patients with Richter's syndrome: early results from phase 1b\/2 trial (EPCORE CLL-1)","volume":"140","author":"Kater","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105444_bib0074","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps3089","article-title":"First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+ B-cell malignancies previously treated with anti-CD20 therapy","volume":"33","author":"Brownstein","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0075","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-179818","article-title":"Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"142","author":"Ayyappan","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0076","doi-asserted-by":"crossref","first-page":"287ra270","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.exphem.2026.105444_bib0077","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u2018Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"key":"10.1016\/j.exphem.2026.105444_bib0078","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell\u2013dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2026.105444_bib0079","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1074\/jbc.M116.748525","article-title":"Engineering an IgG scaffold lacking effector function with optimized developability","volume":"292","author":"Jacobsen","year":"2017","journal-title":"J Biol Chem."},{"key":"10.1016\/j.exphem.2026.105444_bib0080","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","article-title":"Mosunetuzumab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs."},{"key":"10.1016\/j.exphem.2026.105444_bib0081","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2297450","article-title":"Antibodies to watch in 2024","volume":"16","author":"Crescioli","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.exphem.2026.105444_bib0082","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.exphem.2026.105444_bib0083","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241091","article-title":"Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFN\u03b3\/CXCL10-dependent peripheral T cell recruitment in humanized murine model","volume":"16","author":"Cremasco","year":"2021","journal-title":"PLoS One."},{"key":"10.1016\/j.exphem.2026.105444_bib0084","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282147","article-title":"LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity","volume":"18","author":"Mausser","year":"2023","journal-title":"PLoS One."},{"key":"10.1016\/j.exphem.2026.105444_bib0085","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Br\u00f6ske","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.exphem.2026.105444_bib0086","first-page":"1269","article-title":"Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma","volume":"109","author":"Song","year":"2024","journal-title":"Haematologica."},{"key":"10.1016\/j.exphem.2026.105444_bib0087","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine."},{"key":"10.1016\/j.exphem.2026.105444_bib0089","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0090","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s40265-023-01930-4","article-title":"Epcoritamab: first approval","volume":"83","author":"Frampton","year":"2023","journal-title":"Drugs."},{"key":"10.1016\/j.exphem.2026.105444_bib0091","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1168622","article-title":"T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions","volume":"13","author":"Russler-Germain","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2026.105444_bib0092","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-023-01488-4","article-title":"CD20 \u00d7 CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting","volume":"16","author":"Liu","year":"2023","journal-title":"J Hematol Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0093","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.exphem.2026.105444_bib0094","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Scientific Rep."},{"key":"10.1016\/j.exphem.2026.105444_bib0095","unstructured":"Odronextamab BLA accepted for FDA review for the treatment of relapsed\/refractory follicular lymphoma, 26 February 2025, News release. Regeneron Pharmaceuticals, Inc.: Regeneron Pharmaceuticals, Inc. https:\/\/investor.regeneron.com\/node\/30751\/pdf"},{"key":"10.1016\/j.exphem.2026.105444_bib0096","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.exphem.2026.105444_bib0097","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2021-2-4","article-title":"Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma","volume":"10","author":"Castaneda-Puglianini","year":"2021","journal-title":"Drugs Context"},{"key":"10.1016\/j.exphem.2026.105444_bib0098","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1182\/blood-2021-144350","article-title":"Safety and Anti-Tumor Activity of plamotamab (XmAb13676), an anti-CD20 x anti-CD3 bispecific antibody subjects with relapsed\/refractory non-Hodgkin's lymphoma","volume":"138","author":"Patel","year":"2021","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.exphem.2026.105444_bib0099","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1182\/blood-2022-163235","article-title":"Pharmacodynamics and biomarker correlates of imvotamab (IGM-2323), the ffirst-in-class CD20xCD3 bispecific IgM antibody with dual mechanisms of action patients with advanced B cell malignancies","volume":"140","author":"Hernandez","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/blood-2021-153355","article-title":"A phase 1 dose escalation study of Igm-2323, a novel anti-CD20 x anti-CD3 IgM T cell engager (TCE) in patients with advanced B-cell malignancies","volume":"138","author":"Budde","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0101","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/bjh.13242","article-title":"Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies","volume":"169","author":"Schuster","year":"2015","journal-title":"Br J Haematol."},{"key":"10.1016\/j.exphem.2026.105444_bib0102","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1054\/bjoc.2000.1237","article-title":"The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells","volume":"83","author":"Zeidler","year":"2000","journal-title":"Br J Cancer."},{"key":"10.1016\/j.exphem.2026.105444_bib0103","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1479-5876-11-160","volume":"11","author":"Buhmann","year":"2013","journal-title":"J Transl Med."},{"key":"10.1016\/j.exphem.2026.105444_bib0104","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1479-5876-11-160","volume":"11","author":"Buhmann","year":"2013","journal-title":"J Transl Med."},{"key":"10.1016\/j.exphem.2026.105444_bib0105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/bjh.13242","article-title":"Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies","volume":"169","author":"Schuster","year":"2015","journal-title":"Br J Haematol."},{"key":"10.1016\/j.exphem.2026.105444_bib0106","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MOH.0000000000000176","article-title":"Activated T cells armed with bispecific antibodies kill tumor targets","volume":"22","author":"Bhutani","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.exphem.2026.105444_bib0107","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-4939-7553-2_8","article-title":"Bispecific antibody armed T cells to target cancer cells","volume":"1722","author":"Thakur","year":"2018","journal-title":"Methods Mol Biol."},{"key":"10.1016\/j.exphem.2026.105444_bib0108","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.exphem.2005.01.007","article-title":"T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro","volume":"33","author":"Gall","year":"2005","journal-title":"Exp Hematol."},{"key":"10.1016\/j.exphem.2026.105444_bib0109","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13045-024-01646-2","article-title":"Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRP\u03b1, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1\/2 study","volume":"17","author":"Yang","year":"2024","journal-title":"J Hematol Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"Biomark Res."},{"key":"10.1016\/j.exphem.2026.105444_bib0111","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J Hematol Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0112","article-title":"Phase I safety and preliminary efficacy of IMM0306 in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma","volume":"42","author":"Liu","year":"2024","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0113","doi-asserted-by":"crossref","first-page":"12059","DOI":"10.1182\/blood-2022-164746","article-title":"Trial in progress: first report of the phase 1\/2 study of the safety and efficacy of CPO107, a bispecific agent targeting CD20\/CD47 CD20 expressing non-Hodgkin lymphoma (NHL)","volume":"140","author":"Skarbnik","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0114","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.V128.22.620.620","article-title":"DI-Leu16-IL2, an anti-CD20-Interleukin-2 immunocytokine, is safe and active in patients with relapsed and refractory B-cell lymphoma: a report of maximum tolerated dose, optimal biologic dose, and recommended phase 2 dose","volume":"128","author":"Lansigan","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR-T cell therapy for lymphoma","volume":"67","author":"Ramos","year":"2016","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.exphem.2026.105444_bib0116","first-page":"802","article-title":"CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"14","author":"Davila","year":"2016","journal-title":"Clin Adv Hematol Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0117","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res."},{"key":"10.1016\/j.exphem.2026.105444_bib0118","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4241864","article-title":"Application of chimeric antigen receptor T cells in the treatment of hematological malignancies","volume":"2020","author":"Yan","year":"2020","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.exphem.2026.105444_bib0119","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PPO.0000000000000028","article-title":"4-1BB chimeric antigen receptors","volume":"20","author":"Campana","year":"2014","journal-title":"Cancer J."},{"key":"10.1016\/j.exphem.2026.105444_bib0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/asheducation.V2012.1.143.3798224","article-title":"Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen","volume":"2012","author":"Brentjens","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.exphem.2026.105444_bib0121","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to address chimeric antigen receptor tonic signaling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol Cancer Ther."},{"key":"10.1016\/j.exphem.2026.105444_bib0122","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.exphem.2026.105444_bib0123","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.exphem.2026.105444_bib0124","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","article-title":"Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0125","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/bloodadvances.2017011254","article-title":"Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K\u03b4 inhibitors and VIP antagonists","volume":"2","author":"Petersen","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.exphem.2026.105444_bib0126","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0127","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/ajh.27488","article-title":"C-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy: a phase I clinical study","volume":"99","author":"Li","year":"2024","journal-title":"Am J Hematol."},{"key":"10.1016\/j.exphem.2026.105444_bib0128","article-title":"Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy","volume":"39","author":"Liang","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0129","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","article-title":"CD19\/CD20 bispecific chimeric antigen receptor (CAR) in naive\/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.exphem.2026.105444_bib0130","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med."},{"key":"10.1016\/j.exphem.2026.105444_bib0131","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-175007","article-title":"Efficacy and safety of a third generation CD20 CAR-T (MB-106) for treatment of relapsed\/refractory indolent B-cell non-Hodgkin lymphoma: phase-1 results from a multicenter trial","volume":"142","author":"Shadman","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0132","article-title":"Treatment of CD20-directed chimeric antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report","volume":"1","author":"Zhang","year":"2016","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.exphem.2026.105444_bib0133","article-title":"C-CAR039, a novel anti-CD20\/CD19 bi-specific CAR T-cell therapy shows deep and durable clinical benefits in patients with relapsed or refractory (r\/r) B-cell non-Hodgkin lymphoma (B-NHL) in long term follow up","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105444_bib0134","doi-asserted-by":"crossref","first-page":"12784","DOI":"10.1182\/blood-2022-164650","article-title":"Trial in progress: a randomized phase II study of MB-CART2019.1 compared to standard of care therapy in patients with relapsed\/refractory DLBCL ineligible for high-dose chemotherapy and autologous stem cell transplantation - DALY 2-EU trial","volume":"140","author":"Borchmann","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0135","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-141515","article-title":"Improved safety and efficacy of a multi-target chimeric antigen receptor modified T cell therapy (4SCAR2.0) against relapsed or refractory lymphomas","volume":"136","author":"Zhang","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0136","series-title":"62nd ASH Annual Meeting and Exposition","article-title":"Third generation CD20 targeted CAR T-cell therapy (MB-106) for treatment of patients with relapsed\/refractory B-cell non-Hodgkin Lymphoma","author":"Mazyar Shadman","year":"2020"},{"key":"10.1016\/j.exphem.2026.105444_bib0137","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2023-175007","article-title":"Efficacy and safety of a third generation CD20 CAR-T (MB-106) for treatment of relapsed\/refractory indolent B-cell non-Hodgkin lymphoma: phase-1 results from a multicenter trial","volume":"142","author":"Shadman","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105444_bib0138","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T Cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.exphem.2026.105444_bib0139","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-187614","article-title":"A CD19\/CD20-directed bispecific CAR-T cell therapy in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL)","volume":"142","author":"Larson","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0140","article-title":"Adaptive manufacturing of LV20.19 CAR T-cells for relapsed, refractory mantle cell lymphoma","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105444_bib0141","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia."},{"key":"10.1016\/j.exphem.2026.105444_bib0142","article-title":"Phase 1 study of trispecific anti-CD20, anti-CD19, anti-CD22 (CAR20.19.22) T cells for relapsed, refractory B-cell malignancies","volume":"144","author":"Shah","year":"2024","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0143","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0144","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1423183","article-title":"FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy","volume":"7","author":"Pyrzynska","year":"2018","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.exphem.2026.105444_bib0145","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2011.11","article-title":"The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations","volume":"1","author":"Mishima","year":"2011","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.exphem.2026.105444_bib0146","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1111\/cas.15055","article-title":"Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1\/CD20","volume":"112","author":"Jiang","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.exphem.2026.105444_bib0147","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2023020400","article-title":"Alternative splicing of its 5\u2032-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies","volume":"142","author":"Ang","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0148","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clim.2008.03.507","article-title":"Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity","volume":"128","author":"Guo","year":"2008","journal-title":"Clin Immunol."},{"key":"10.1016\/j.exphem.2026.105444_bib0149","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1363102","article-title":"Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells","volume":"15","author":"Dabkowska","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.exphem.2026.105444_bib0150","doi-asserted-by":"crossref","first-page":"eabj3286","DOI":"10.1126\/sciadv.abj3286","article-title":"When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer","volume":"8","author":"Hasim","year":"2022","journal-title":"Sci Adv."},{"key":"10.1016\/j.exphem.2026.105444_bib0151","doi-asserted-by":"crossref","DOI":"10.3390\/mps8050108","article-title":"Mechanisms of resistance to CAR T-cells and how to overcome them","volume":"8","author":"Legato","year":"2025","journal-title":"Methods Protoc."},{"key":"10.1016\/j.exphem.2026.105444_bib0152","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1038\/s41467-024-51978-3","article-title":"IL-4 drives exhaustion of CD8(+) CART cells","volume":"15","author":"Stewart","year":"2024","journal-title":"Nat Commun."},{"key":"10.1016\/j.exphem.2026.105444_bib0153","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood-2024-208372","article-title":"Intrinsic tumor drivers and immune escape mechanisms in CD19 CAR T-cell therapy resistance for aggressive large B cell lymphoma","volume":"144","author":"Ziccheddu","year":"2024","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105444_bib0154","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia."},{"key":"10.1016\/j.exphem.2026.105444_bib0155","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nri.2017.103","article-title":"Regulation of immunity and inflammation by hypoxia in immunological niches","volume":"17","author":"Taylor","year":"2017","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.exphem.2026.105444_bib0156","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832645","article-title":"Armored BCMA CAR T cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-\u03b2","volume":"13","author":"Alabanza","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.exphem.2026.105444_bib0157","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.exphem.2026.105444_bib0158","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1182\/bloodadvances.2022009480","article-title":"Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy","volume":"7","author":"Lee","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.exphem.2026.105444_bib0159","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004348","article-title":"Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway","volume":"10","author":"Shen","year":"2022","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.exphem.2026.105444_bib0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1746-1596-6-33","article-title":"The predictive significance of CD20 expression in B-cell lymphomas","volume":"6","author":"Prevodnik","year":"2011","journal-title":"Diagn Pathol."},{"key":"10.1016\/j.exphem.2026.105444_bib0161","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1200\/JCO.2004.06.003","article-title":"Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype","volume":"22","author":"Weng","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105444_bib0162","first-page":"1454","article-title":"Fc\u03b3RIIa-H131R variant is associated with inferior response in diffuse large B cell lymphoma: a meta-analysis of genetic risk","volume":"21","author":"Ziakas","year":"2016","journal-title":"J BUON."},{"key":"10.1016\/j.exphem.2026.105444_bib0163","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/leu.2011.378","article-title":"BCL2 mutations in diffuse large B-cell lymphoma","volume":"26","author":"Schuetz","year":"2012","journal-title":"Leukemia."},{"key":"10.1016\/j.exphem.2026.105444_bib0164","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/modpathol.2016.92","article-title":"Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine","volume":"29","author":"Sun","year":"2016","journal-title":"Mod Pathol."},{"key":"10.1016\/j.exphem.2026.105444_bib0165","article-title":"The effect of the tumor microenvironment on lymphoid neoplasms derived from B cells","volume":"12","author":"Ingravallo","year":"2022","journal-title":"Diagnostics (Basel)."},{"key":"10.1016\/j.exphem.2026.105444_bib0166","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-11128-1","article-title":"CD20-bearing extracellular vesicles are associated with prognostic biomarkers of patients with AIDS-NHL","volume":"15","author":"Mart\u00ednez","year":"2025","journal-title":"Sci Rep."},{"key":"10.1016\/j.exphem.2026.105444_bib0167","doi-asserted-by":"crossref","first-page":"15336","DOI":"10.1073\/pnas.1102855108","article-title":"Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3","volume":"108","author":"Aung","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.exphem.2026.105444_bib0168","doi-asserted-by":"crossref","first-page":"156","DOI":"10.18632\/oncoscience.633","article-title":"Targeted therapies and resistance mechanisms in lymphoma: current landscape and emerging solutions","volume":"12","author":"Tiwari","year":"2025","journal-title":"Oncoscience."},{"key":"10.1016\/j.exphem.2026.105444_bib0169","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.2147\/JIR.S499403","article-title":"The benefits and safety of monoclonal antibodies: implications for cancer immunotherapy","volume":"18","author":"Zhang","year":"2025","journal-title":"J Inflamm Res."},{"key":"10.1016\/j.exphem.2026.105444_bib0170","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1709.1709","article-title":"Long-term remission (>3 years) after rituximab monotherapy used for patients with relapsed indolent non-Hodgkin lymphomas (NHL)","volume":"124","author":"Michallet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105444_bib0171","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/S2352-3026(25)00034-1","article-title":"Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial","volume":"12","author":"Northend","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.exphem.2026.105444_bib0172","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2217\/imt-2017-0062","article-title":"Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis","volume":"9","author":"Riaz","year":"2017","journal-title":"Immunotherapy."}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:43:41Z","timestamp":1785908621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X26000779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":172,"alternative-id":["S0301472X26000779"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105444","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD20-targeted immunotherapies in B-cell malignancies: mechanistic and clinical advances","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Experimental Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105444"}}